Gamma Knife Controls Craniopharyngioma but Symptom-Driven Interventions Remain Common

Long-Term Management Challenges in Craniopharyngioma

Craniopharyngiomas are histologically benign but clinically aggressive epithelial tumors that frequently adhere to critical neurovascular structures, making complete surgical resection difficult [1, 2, 3]. Despite high survival rates, patients often face significant long-term morbidity from panhypopituitarism (the inadequate production of all anterior pituitary hormones), visual deficits, and hypothalamic dysfunction (damage to the brain region regulating appetite, temperature, and sleep) [2, 3]. Gamma Knife radiosurgery has emerged as a standard adjuvant or salvage therapy for residual and recurrent disease, with meta-analytic data demonstrating a five-year progression-free survival (the period during and after treatment where the tumor does not grow) of 70% (95% CI: 64-76%) [4, 5]. However, long-term efficacy data remain sparse because these tumors can recur decades after initial treatment; for instance, a nationwide cohort with a mean follow-up of 21 years found that the progression-free survival rate drops to 40% at 30 years [6, 7]. A new retrospective study of 72 patients now provides critical long-term data on radiographic control and identifies a gross tumor volume (the total visible extent of the tumor on imaging) of less than 2.0 cubic centimeters as a predictor of superior treatment success [8].

Defining Success Beyond Radiographic Stability

Managing craniopharyngiomas requires a delicate balance between tumor control and the preservation of the optic chiasm and hypothalamus, structures often compromised by these sellar and suprasellar lesions. To evaluate the long-term efficacy of stereotactic radiosurgery, researchers conducted a retrospective single-center cohort study of 72 patients treated with Gamma Knife radiosurgery. The study population had a median age of 32.5 years, representing a cohort facing decades of potential survivorship and cumulative treatment toxicity. The researchers delivered a median margin dose (the radiation dose delivered to the outer edge of the tumor) of 11.5 Gy, a standard therapeutic range intended to achieve local control while minimizing damage to adjacent healthy tissue. This longitudinal analysis utilized a median follow-up period of 108.2 months, providing a rigorous look at the durability of treatment over more than nine years, which is essential for capturing the late recurrences characteristic of these slow-growing epithelial tumors.

The investigators established a primary end point of clinically relevant disease control failure, a composite metric defined as radiographic progression (including both solid and cystic growth) or the necessity of any craniopharyngioma-directed intervention following Gamma Knife radiosurgery. This definition acknowledges that for practicing clinicians, a stable image on a scan does not always equate to a successful outcome if the patient requires further invasive procedures to manage symptoms. By tracking both imaging and clinical interventions, the study addresses the gap between radiological appearance and the actual patient experience, where cystic expansions or hormonal shifts may necessitate action despite a stable solid tumor component.

High Survival Rates and the Burden of Reintervention

Long-term data from this cohort demonstrate that Gamma Knife radiosurgery is associated with high rates of life expectancy, with an overall survival of 93.6% at 5 years and 88.9% at 10 years. While these survival figures are favorable, the study utilized secondary end points, including radiographic progression alone and overall survival, to provide a more granular view of treatment efficacy. These metrics revealed a complex clinical picture where survival does not necessarily equate to a lack of further medical or surgical necessity. Despite the high survival rates, clinically relevant disease control failure occurred in 25 out of 72 patients (34.7%), highlighting a significant burden of ongoing disease management.

A critical finding of the study is the disparity between imaging results and the need for clinical action. While Gamma Knife radiosurgery achieved durable radiographic control in the majority of the cohort, radiographic progression (the growth of solid or cystic tumor components visible on imaging) accounted for only 5 out of 72 cases (6.9%). In contrast, symptom-driven interventions were far more frequent, occurring in 20 out of 72 patients (27.8%). These interventions were required to manage clinical symptoms even when imaging did not show overt tumor growth, suggesting that radiographic stability alone is an insufficient metric for defining success. For the small subset of patients who did experience radiographic failure, the progression occurred at a median of 15.0 months following treatment. In all five of these cases, the progression was managed with salvage resection (a follow-up surgical procedure to remove recurring tumor tissue). Because symptom-driven interventions were common and often occurred independently of clear imaging changes, the authors concluded that these clinical requirements should be formally incorporated into disease control endpoints to accurately reflect the clinical reality of managing this disease.

Volume and Dose Thresholds for Tumor Control

Tumor size at the time of treatment appears to be the most significant predictor of long-term radiographic stability, with larger volume associated with worse radiographic control. When analyzing the gross tumor volume (the total volume of the tumor as defined by neuroimaging), the researchers found that radiographic failure was significantly lower in patients with a volume of less than 2.0 cm3. In this smaller tumor subgroup, only 1 out of 44 patients (2.3%) experienced radiographic progression. In contrast, patients with a volume of 2.0 cm3 or greater faced a substantially higher failure rate, with 4 out of 26 patients (15.4%) showing evidence of tumor growth on follow-up imaging. This suggests that early intervention when residuals are small may optimize the chances of long-term stability.

Further analysis of the larger tumors (GTV ≥2.0 cm3) suggests that the radiation dose delivered to the tumor periphery may influence these outcomes. Within this higher-volume group, no radiographic failures occurred in the 7 patients who received a margin dose of 12.5 Gy or higher. Conversely, all 4 radiographic failures in the larger tumor cohort occurred among the 19 patients treated with a margin dose of less than 12.5 Gy. While these data suggest a potential therapeutic threshold, the researchers noted that this signal suggesting a benefit for a dose of 12.5 Gy or greater in higher-volume tumors warrants validation in larger, prospective cohorts. For the practicing clinician, these findings indicate that while Gamma Knife radiosurgery is highly effective for small residuals, larger tumors may require more aggressive dosing strategies, balanced against the risk to nearby structures, to maintain radiographic stability.

References

1. Cuny T, Reynaud R, Raverot G, et al. Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement. Annales d Endocrinologie. 2024. doi:10.1016/j.ando.2024.07.002

2. Amayiri N, Spitaels A, Zaghloul MS, et al. SIOP PODC–adapted treatment guidelines for craniopharyngioma in low‐ and middle‐income settings. Pediatric Blood & Cancer. 2020. doi:10.1002/pbc.28493

3. Javidialsaadi M, Luy DD, Smith H, Cecia A, Yang SD, Germanwala AV. Advances in the Management of Craniopharyngioma: A Narrative Review of Recent Developments and Clinical Strategies. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14041101

4. Albano L, Losa M, Barzaghi LR, et al. Gamma Knife Radiosurgery for Pituitary Tumors: A Systematic Review and Meta-Analysis. Cancers. 2021. doi:10.3390/cancers13194998

5. Pahwa B, Mahajan S, Pahwa N, Panico N, Sheehan JP. Linear regression models predict survival and complication rates in patients undergoing gamma knife radiosurgery for recurrent and residual craniopharyngiomas: a meta-analysis of 743 tumors.. Journal of neuro-oncology. 2025. doi:10.1007/s11060-025-05196-6

6. Buwaider A, Kananathan M, Tabari S, et al. Long-Term Outcomes After Gamma Knife Radiosurgery Treatment of Craniopharyngiomas: A Swedish Nationwide Cohort With a Mean Follow-Up of 21 Years.. Neurosurgery. 2025. doi:10.1227/neu.0000000000003394

7. Lin Z, Lin Y. P14.20.A GAMMA KNIFE RADIOSURGERY FOR PAPILLARY CRANIOPHARYNGIOMA AFTER SURGERY: A SINGLE-CENTER STUDY ON TUMOR CONTROL AND PREDICTORS OF RECURRENCE. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf193.481

8. Reyes JS, Bouras A, Hadjipanayis CG, Lunsford LD, Niranjan A. Long-Term Outcomes After Gamma Knife Radiosurgery for Craniopharyngioma: A Single-Center Retrospective Study.. Neurosurgery. 2026. doi:10.1227/neu.0000000000004081